Foghorn Therapeutics director granted 28,000 stock options

Foghorn Therapeutics Inc. director Ian F. Smith received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share.

Accepted by SEC EDGAR 06/25/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. director Ian F. Smith received a grant of stock options covering 28,000 shares of common stock at an exercise price of $4.08 per share. These options vest in full on the first anniversary of the grant date, contingent on his continued board service, and expire on June 23, 2036. Following this compensation award, Smith holds 28,000 options directly, and the filing reports no open-market buying or selling activity.

Insider Trade Summary

Grant/Award: 28,000 shares

Grant/Award 1 txn

Insider SMITH IAN F

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	28,000	$4.08	$114K

Holdings After Transaction: Stock Options (Right to buy) — 28,000 contracts (Direct)

Holdings Before and After: Stock Options (Right to buy), 0 to 28,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Key Figures

Options granted: 28,000 options Exercise price: $4.08 per share Post-grant holdings: 28,000 options +2 more

5 metrics

Options granted 28,000 options Stock options covering common stock granted to director

Exercise price $4.08 per share Exercise price for the 28,000 stock options

Post-grant holdings 28,000 options Total derivative securities held following the grant

Vesting schedule 100% after 1 year Vests in full on first anniversary of grant date

Expiration date June 23, 2036 Option expiration date for the 28,000 options

Key Terms

Stock Options (Right to buy), grant, award, or other acquisition, exercise price, vests in full, +1 more

5 terms

Stock Options (Right to buy) financial

"security_title: Stock Options (Right to buy)"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 4.0800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"The option vests in full on the first anniversary of the grant date"

expiration date financial

"expiration_date: 2036-06-23T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Foghorn Therapeutics (FHTX) report for Ian F. Smith?

Foghorn Therapeutics reported a stock option grant to director Ian F. Smith. He received options for 28,000 shares of common stock as a compensation award, rather than buying shares on the market, according to the Form 4 filing.

How many FHTX shares are covered by Ian F. Smith’s new stock options?

The new stock option grant covers 28,000 shares of Foghorn Therapeutics common stock. These options give Smith the right to buy that number of shares at a fixed exercise price if he meets the vesting conditions.

What is the exercise price of Ian F. Smith’s Foghorn Therapeutics stock options?

The exercise price of Ian F. Smith’s options is $4.08 per share. This means he can purchase Foghorn Therapeutics common stock at $4.08 per share once the options vest and before they expire.

When do Ian F. Smith’s Foghorn Therapeutics stock options vest?

The options vest in full on the first anniversary of the grant date. Vesting is subject to Smith’s continued service on the company’s board of directors, aligning his compensation with ongoing governance responsibilities.

When do Ian F. Smith’s Foghorn Therapeutics stock options expire?

The stock options expire on June 23, 2036, if not exercised earlier. After this expiration date, Smith would no longer be able to use the options to purchase Foghorn Therapeutics common stock at the exercise price.

Did Ian F. Smith buy or sell FHTX shares on the open market in this Form 4?

No open-market purchases or sales were reported in this Form 4. The filing only shows a compensation-related acquisition of stock options, not a market trade in Foghorn Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH IAN F

(Last) (First) (Middle)

99 COOLIDGE AVENUE

STE 500

(Street)

WATERTOWN MASSACHUSETTS 02742

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$4.08	06/24/2026		A		28,000		(1)	06/23/2036	Common Stock	28,000	$4.08	28,000	D

Explanation of Responses:

1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Ian F. Smith	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)